Dannex Ayrton Starwin Plc

GHSE:DASPHARMA Stock Report

Market Cap: GH₵0

Dannex Ayrton Starwin Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Daniel Kwabena Kissi

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenure3yrs

Recent management updates

Recent updates


CEO

Daniel Kwabena Kissi (57 yo)

no data

Tenure

Mr. Daniel Kwabena Apeagyei Kissi has been Managing Director of Ayrton Drugs Manufacturing Company Ltd. since December 01, 2012 and also it's Chief Executive Officer. He has been Chief Executive Officer an...


Board Members

NamePositionTenureCompensationOwnership
Theophilus Amarteifio
Executive Chairmanno datano datano data
Daniel Kwabena Kissi
CEO & Executive Directorno datano datano data
Henry Ocansey
CFO & Executive Director3yrsno datano data
Kwasi Yirenkyi
Chief Corporate Affairs & Communications Officer and Non-Executive Director3yrsno datano data
Alex Kwabena Bonney
Non-Executive Directorno datano datano data
Barima Afrane
Non-Executive Directorno datano datano data
Amarteokor Amarteifio
Non-Executive Directorno datano datano data
Benjamin Agyeman
Non-Executive Director3yrsno datano data
Moritz Acquah
Non-Executive Director1.9yrsno datano data

3.0yrs

Average Tenure

73yo

Average Age

Experienced Board: DASPHARMA's board of directors are considered experienced (3 years average tenure).